Alnylam Pharmaceuticals Inc
ALNYHealthcare|Biotechnology|USA
$298.76
-14.03 (-4.49%)
Tangible Book
$8.06
Graham Number
$32.23
Upcoming Data Readouts (22)
Dec 2026
Est. completion
Apr 2027
Est. completion
Acute Hepatic Porphyria
ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
NCT04883905n=150
Apr 2027
Est. completion
May 2027
Est. completion
P2Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
NCT07465224n=40
Jul 2027
Est. completion
Aug 2027
Est. completion
P2Cerebral Amyloid Angiopathy
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
NCT06393712n=200
Aug 2027
Est. completion
P1P2Obese or Overweight Healthy Volunteers
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
NCT06845202n=144
Sep 2027
Est. completion
P1Advanced Hepatocellular Carcinoma
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
NCT06600321n=158
Dec 2027
Est. completion
Hereditary Amyloidosis, Transthyretin-Related
Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin (TTR) Variants and Patients With Hereditary Transthyretin-mediated (hATTR) Amyloidosis With Polyneuropathy
NCT06360289n=346
Dec 2027
Est. completion
Dec 2027
Est. completion
P3Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
NCT07223203n=125
Jan 2028
Est. completion
P1P2Hereditary Hemorrhagic Telangiectasia
A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
NCT06659640n=120
Apr 2028
Est. completion
P2Hypertension
A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran
NCT07553442n=93
Jul 2028
Est. completion
P1Huntington's Disease
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
NCT06585449n=66
Sep 2028
Est. completion
Primary Hyperoxaluria Type 1
BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)
NCT04982393n=207
Apr 2029
Est. completion
P1Early-Onset Alzheimer Disease
A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
NCT05231785n=60
Mar 2030
Est. completion
P1Alzheimer's Disease
A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
NCT07214727n=50
May 2030
Est. completion
P3Transthyretin Amyloidosis With Cardiomyopathy
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT07052903n=1,250
Sep 2030
Est. completion
P3High Risk Cardiovascular Disease
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
NCT07181109n=11,000
Oct 2030
Est. completion
Hereditary Transthyretin-mediated (hATTR) Amyloidosis
Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
NCT05040373n=10
Awaiting Results (1)
Trials past primary completion date but still active — data readout may be imminent.
May 2024
P3
HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT04153149